Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Traditional Chinese Medicine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Yiling Pharmaceutical's Patent Depression-resolving Drug Approved for Marketing in China
Details : According to the decreased values for main efficacy indicators of the Hamilton Depression Scale scores from the baseline, the efficacy of the test group was better than that of the placebo group, and also not inferior to that of the fluoxetine hydrochlor...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 22, 2021
Lead Product(s) : Traditional Chinese Medicine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lianhua Qingwen
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Recipient : Xiamen University
Deal Size : Not Applicable
Deal Type : Not Applicable
New Progress in Study on Mechanism of Lianhua Qingwen Capsules for Treatment of COVID-19
Details : The study result, "Screening of the Anti-COVID-19 Pharmacological Active Ingredients of Traditional Chinese Medicine Lianhua Qingwen Capsules (KT07) Based on Human Exposure and ACE2 Biochromatography", was published in the top journal of pharmacology.
Brand Name : KT07
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 26, 2021
Lead Product(s) : Lianhua Qingwen
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Recipient : Xiamen University
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lisinopril
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Preparation Products of Yiling Pharma Approved by FDA for Launch in the US Market
Details : The announcement showed that Lisinopril Tablets are mainly used for the treatment of essential hypertension (EH) and renal vascular hypertension (RVH) and were originally researched and developed by Astrazeneca and approved for launch in the United State...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 19, 2020
Lead Product(s) : Lisinopril
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lianhua Qingwen
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lianhua Qingwen Receives First International Approval for Covid-19 Treatment
Details : Lianhua Qingwen Capsules was approved to be registered as a drug to treat symptoms like fever, cough, debilitation, sore muscles, nasal obstruction, runny nose, headaches, a dry and sore throat, shortness of breath, and a red tongue caused by viral disea...
Brand Name : KT07
Molecule Type : Undisclosed
Upfront Cash : Not Applicable
September 05, 2020
Lead Product(s) : Lianhua Qingwen
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
